MentionFox
Home › Stakes › Cellectar Biosciences, Inc.
5%+ stakes · Schedule 13D and 13G

Cellectar Biosciences, Inc.: 5%+ holders

Who has reported owning 5% or more of Cellectar Biosciences, Inc., from Schedule 13D and 13G filings: each holder's stake as filed, the timeline, and the purpose each 13D states, quoted.

At 5% or more9
Filings17
Latest filing2026-08-14

Cellectar Biosciences, Inc. has 17 Schedule 13D or 13G filings on record since 2025-07-08. 9 holders' latest filing reports 5% or more of common stock, $0.00001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

HolderPercentSharesLatestEvent date
Bleichroeder LP9.99%808,300SCHEDULE 13G, 2026-08-132026-06-30
Janus Henderson Group Plc9.99%798,382SCHEDULE 13G, 2026-06-052026-05-29
Empery Asset Management, LP9.99%864,090SCHEDULE 13G, 2026-08-042026-06-30
SilverArc Capital Management, LLC9.99%851,285SCHEDULE 13G, 2026-08-142026-06-30
Balyasny Asset Management L.P.9.99%798,382SCHEDULE 13G, 2026-08-142026-06-30
Stonepine Capital Management, LLC9.9%863,277SCHEDULE 13G, 2026-05-112026-05-04
StemPoint Capital LP9.9%845,740SCHEDULE 13G, 2026-08-142026-06-30
Caligan Partners LP5.9%469,998SCHEDULE 13G, 2026-08-142026-06-30
Rosalind Advisors, Inc.5.5%247,715SCHEDULE 13G/A, 2026-02-102025-12-31
Mitchell P. Kopin4.99%140,101SCHEDULE 13G, 2025-07-082025-07-01
Hexstone Capital LLC4.9%216,130SCHEDULE 13G/A, 2026-02-042025-12-31
Lytton Laurence W1.6%51,391SCHEDULE 13G/A, 2025-08-142025-06-30
ADAR1 Capital Management, LLC0.1%2,962SCHEDULE 13G/A, 2025-08-142025-06-30
Nantahala Capital Management, LLC0.06%1,109SCHEDULE 13G/A, 2025-08-142025-06-30

Timeline

FiledHolderPercentFiling
2025-07-08Mitchell P. Kopin4.99%SCHEDULE 13G
2025-08-08Hexstone Capital LLC5.6%SCHEDULE 13G
2025-08-14Lytton Laurence W1.6%SCHEDULE 13G/A
2025-08-14Nantahala Capital Management, LLC0.06%SCHEDULE 13G/A
2025-08-14ADAR1 Capital Management, LLC0.1%SCHEDULE 13G/A
2025-11-14Bleichroeder LP6.08%SCHEDULE 13G
2026-02-04Hexstone Capital LLC4.9%SCHEDULE 13G/A
2026-02-10Rosalind Advisors, Inc.5.5%SCHEDULE 13G/A
2026-02-13Bleichroeder LP4.61%SCHEDULE 13G/A
2026-05-11Stonepine Capital Management, LLC9.9%SCHEDULE 13G
2026-06-05Janus Henderson Group Plc9.99%SCHEDULE 13G
2026-08-04Empery Asset Management, LP9.99%SCHEDULE 13G
2026-08-13Bleichroeder LP9.99%SCHEDULE 13G
2026-08-14StemPoint Capital LP9.9%SCHEDULE 13G
2026-08-14SilverArc Capital Management, LLC9.99%SCHEDULE 13G
2026-08-14Balyasny Asset Management L.P.9.99%SCHEDULE 13G
2026-08-14Caligan Partners LP5.9%SCHEDULE 13G
RSS

Tools for this story

Each opens in a new tab, filled in for Cellectar Biosciences, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes

Cite this page

Permanent URL: https://mentionfox.com/stakes/cellectar-biosciences
Last updated 2026-09-27
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Cellectar Biosciences, Inc. 5%+ holders: 9 at 5% or more, largest Bleichroeder LP 9.99%. MentionFox, 2026-09-27. https://mentionfox.com/stakes/cellectar-biosciences